The Netherlands-based plant has instead focused on making a different, possibly more profitable vaccine aimed at a different virus, The New York Times reported, citing people familiar with the matter.
It is unclear whether vaccine supplies have been been affected by the company's move, according to the report. J&J is preparing to have the Leiden plant restart Covid vaccine production in March, the Times reported.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: